International and domestic collaboration will enhance India’s business outlook-Health News, Firstpost

COVID-19 (New Coronavirus Infection) It clearly reminded me of the importance of uninterrupted access to medicines and health products. We assume that the capabilities and capabilities of the country’s pharmaceutical industry are very important in this regard.

The importance of the pharmaceutical industry goes beyond the perspective of public health. This can be easily understood from the comparative example. Pioneering modern generation industries such as automobiles are attracting large investments and creating significant jobs around the world. Just as industry outlooks are important to governments, businesses and consumers, automotive supply chain disruptions are less worrisome than pharmaceuticals and pharmaceutical supply chains. The country can survive delays in car delivery, but cannot survive with medicines and essential health products.

Countries with inadequate pharmaceutical capacity in the region are at risk of failing to provide essential health products to people in the following unforeseen challenges: COVID-19 (New Coronavirus Infection) .. The challenges faced by each country in this regard are evident in the global diversity of national immunization.

To date, most African countries have been unable to vaccinate more than a few percent of their population on average. In South and Southeast Asia, the average vaccinated population in most countries is less than 20 percent of the population. High-income Asia-Pacific countries such as Australia and New Zealand also vaccinate less than about one-third of their population. This is in contrast to North America, Western Europe and Southern Europe, where countries are vaccinated. About two-thirds Of their people.

Countries that do not produce vaccines in the country must rely on supply from others to inoculate the population. The World Health Organization’s (WHO) common vaccine pool is inadequate to meet global demand. Therefore, it is not surprising that vaccination rates vary widely around the world.

Access to vaccines to limit the incidence of COVID-19 (New Coronavirus Infection) Is one of the top priorities for all countries, and the role of global vaccine producers has become very important. India plays a very important role in this regard.

India, variously described as the “pharmacy of the world,” has strong local skills to manufacture final dose formulations, biologics (such as vaccines) and other healthcare products (such as surgery). .. A prominent exporter of pharmaceuticals and vaccines to major global markets. As the 11th largest exporter in the world, India accounted for 2.6% of global pharmaceutical exports in 2019. In the same year, India was the seventh largest vaccine exporter, accounting for 3.9% of the world’s vaccine exports.

COVID-19 (New Coronavirus Infection) Vaccines manufactured and distributed by Indian pharmaceutical companies such as the Serum Institute of India (SII), Barrat Biotech and Dr. Reddies Laboratories are widely deployed in India and several other countries to combat pandemics. increase. More local vaccines will soon be available locally and globally, including ZyCoV-D (a needle-free vaccine that can be given to children over the age of 12) by Biological E, Gennova Pharmaceuticals, and Zydus Cadilla.

India’s excellence as a global supplier of vaccines has much to do with the effective foreign cooperation of local pharmaceutical companies. The partnership between AstraZeneca and SII to produce the Cobishield vaccine is well known. Covishield is WHO approved for emergency use and is controlled in several countries. The Sputnik V vaccine, developed by the Russian National Institute of Gamalaya, is distributed in India by Dr. Reddies Laboratories in collaboration with the Russian Infrastructure Development Fund (RIDF).

More co-vaccines are awaited. These include Johnson & Johnson vaccines manufactured by Biological E. This vaccine is a breakthrough product as it is the result of a vaccine partnership announced for production by the Quad Group in the United States, India, Japan and Australia. We distribute vaccines to the vast Indo-Pacific region. Biopharmacy has partnered with Canada’s Providence Therapeutics to manufacture the latter vaccine. Novavax, a US vaccine manufacturer, has also partnered with SII to manufacture vaccines in India.

Business-to-business (B2B) collaboration is essential to strengthen India’s ability to be a world-leading actor in its efforts. COVID-19 (New Coronavirus Infection) .. With these cooperation, there will be no shortage of vaccines in India in the country. Combining foreign financial, technical and marketing expertise with local proficiency in R & D and manufacturing is the best strategy for India and some developing countries to ensure such security. The collaboration puts India in a position of commendable strength to serve its own people and the world.

COVID 19 is igniting new international cooperation for the Indian pharmaceutical industry. The benefits of these collaborations are important for India and the collaborative countries that are home to companies affiliated with Indian pharmaceutical companies.These partnerships extend beyond vaccines to treatment COVID-19 (New Coronavirus Infection) .. A notable example is Gilead’s voluntary licensing agreement with an Indian generic manufacturer to manufacture Remdesivir. COVID-19 (New Coronavirus Infection) Patience; MSD (Merck, Sharpe & Dohme) efforts to authorize local production of Molnupiravir. Collaboration emphasizes the importance of cross-border collaboration for businesses to protect access to critical medicines. In terms of raw material availability, significant inputs, technical capabilities, scale of production, financial resources and distribution networks, no country is sufficient domestically enough to circumvent these partnerships.

In terms of greater economic resilience and self-sufficiency, partnerships in the pharmaceutical industry will greatly help build regional capabilities. NS COVID-19 (New Coronavirus Infection) In this regard, we have provided India with the right opportunities and opportunities. This partnership will enable India to maintain its excellence as a world-leading vaccine producer. They also provide the foundation for the Indian pharmaceutical industry to be a front runner in the manufacture of medicines for future treatments. COVID-19 (New Coronavirus Infection) ..

Public health security, in addition to being a global concern, is of paramount interest to all nations. The fact that India and its major geopolitical allies, the United States, Japan, the United Kingdom, Australia and Canada have decided to work together to expand the global supply of health products is of strategic importance to the pharmaceutical industry. Shows sex.The world’s largest democracies work together COVID-19 (New Coronavirus Infection) Pandemics and medicines will undoubtedly be the starting point for broader international partnerships between countries.

COVID-19 (New Coronavirus Infection) India is in a great position to engage in pharmaceutical cooperation that promotes a larger global association. India needs to seize the opportunity as the world’s best pharmaceutical companies are ready to work with India. This could be an Indian moment that has a decisive impact on the health and security of the world.

The author is a Senior Research Fellow and Research Leader (Trade and Economics) at the Institute of South Asian Studies, National University of Singapore.